Genetic frontotemporal degeneration with dementia

Genetic frontotemporal degeneration with dementia (also known as genetic frontotemporal dementia or familial frontotemporal dementia) is a group of inherited neurodegenerative disorders characterized by progressive deterioration of the frontal and temporal lobes of the brain. This condition encompasses several genetic subtypes caused by mutations in genes such as MAPT (microtubule-associated protein tau), GRN (progranulin), and C9orf72 (chromosome 9 open reading frame 72), among others. The disease primarily affects the central nervous system, leading to progressive cognitive decline, personality and behavioral changes, language difficulties, and eventually dementia. Clinical presentation typically begins in adulthood, often between the ages of 45 and 65, though onset can vary. Patients may initially exhibit behavioral changes including social disinhibition, apathy, loss of empathy, compulsive or ritualistic behaviors, and changes in eating habits. Language variants may present with progressive difficulty in speech production (nonfluent/agrammatic variant) or loss of word meaning (semantic variant). As the disease progresses, patients may develop motor symptoms including parkinsonism or motor neuron disease features, particularly in C9orf72-related cases. Executive function, planning, and judgment are often impaired early in the disease course. Currently, there is no cure or disease-modifying treatment for genetic frontotemporal degeneration with dementia. Management is primarily supportive and symptomatic, including behavioral interventions, speech and language therapy, occupational therapy, and caregiver support. Selective serotonin reuptake inhibitors (SSRIs) may help manage behavioral symptoms such as disinhibition, compulsive behaviors, and agitation. Genetic counseling is recommended for affected families. Research into targeted therapies, including antisense oligonucleotides for C9orf72 mutations and progranulin replacement strategies for GRN mutations, is actively ongoing in clinical trials.

Common questions about Genetic frontotemporal degeneration with dementia